Clinical Trials Directory
Recruiting
Conditions
Sponsors
Search
About
Trials
/
Sponsors
/ Eucure (Beijing) Biopharma Co., Ltd
Eucure (Beijing) Biopharma Co., Ltd
Industry · 12 registered clinical trials.
Status
Trial
Phase
Started
Withdrawn
A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC
HCC, NSCLC Stage IIIB, NSCLC Stage IV
Phase 2
2023-06-01
Unknown
Study of YH004 (4-1BB Agonist Antibody) in Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lympho
Advanced Solid Tumors, Relapsed Or Refractory Non-Hodgkin Lymphoma
Phase 1
2023-01-31
Completed
A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unre
Mucosal Melanoma
Phase 2
2022-06-13
Completed
A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors
Solid Tumor
Phase 1
2022-04-05
Completed
A Study to Assess YH002 in Combination with YH001 in Subjects with Advanced Solid Tumors
Advanced Solid Tumor
Phase 1
2022-02-21
Completed
A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers
Melanoma, Pancreatic Ductal Adenocarcinoma
Phase 2
2021-12-08
Completed
Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy
Cancer
Phase 1
2021-12-07
Completed
A Study to Evaluate YH003 in Subjects With Advanced Solid Tumors
Advanced Solid Tumors
Phase 1
2021-08-26
Completed
A Study to Evaluate YH001 in Subjects With Advanced Solid Tumors
Advanced Solid Tumors
Phase 1
2021-01-26
Completed
A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumo
Advanced Solid Tumors
Phase 1 / Phase 2
2020-08-04
Completed
A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subject
Advanced Solid Malignancies
Phase 1
2020-04-22
Completed
A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors
Advanced Solid Tumor
Phase 1
2020-04-21